PET/CT在结外NK/T细胞淋巴瘤诊治中的应用进展

丁晓芳; 肖晓燕; 柳江燕; 丁晓芳; 肖晓燕; 柳江燕

doi:10.3760/cma.j.cn121381-202012013-00111

[1]

Kim SJ, Yoon DH, Jaccard A, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis[J]. Lancet OncolLancet Oncol, 2016, 17(3): 389-400. doi: 10.1016/S1470-2045(15)00533-1

[2]

Haverkos BM, Pan ZG, Gru AA, et al. Extranodal NK/T cell lymphoma, nasal type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European cases[J]. Curr Hematol Malig RepCurr Hematol Malig Rep, 2016, 11(6): 514-527. doi: 10.1007/s11899-016-0355-9

[3]

Tse E, Kwong YL. NK/T-cell lymphomas[J]. Best Pract Res Clin HaematolBest Pract Res Clin Haematol, 2019, 32(3): 253-261. doi: 10.1016/j.beha.2019.06.005

[4]

Tse E, Kwong YL. How I treat NK/T-cell lymphomas[J]. BloodBlood, 2013, 121(25): 4997-5005. doi: 10.1182/blood-2013-01-453233

[5]

Takata K, Hong ME, Sitthinamsuwan P, et al. Primary cutaneous NK/T-cell lymphoma, nasal type and CD56-positive peripheral T-cell lymphoma: a cellular lineage and clinicopathologic study of 60 patients from Asia[J]. Am J Surg PatholAm J Surg Pathol, 2015, 39(1): 1-12. doi: 10.1097/PAS.0000000000000312

[6]

Kim SJ, Jung HA, Chuang SS, et al. Extranodal natural killer/T-cell lymphoma involving the gastrointestinal tract: analysis of clinical features and outcomes from the Asia Lymphoma Study Group[J/OL]. J Hematol Oncol, 2013, 16(6): 86[2020-12-10]. https://link.springer.com/article/10.1186/1756-8722-6-86. DOI: 10.1186/1756-8722-6-8.

[7]

Lee J, Suh C, Park YH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study[J]. J Clin OncolJ Clin Oncol, 2006, 24(4): 612-618. doi: 10.1200/JCO.2005.04.1384

[8]

Wu HB, Wang QS, Wang MF, et al. Utility of ¹⁸F-FDG PET/CT for staging NK/T-cell lymphomas[J]. Nucl Med CommunNucl Med Commun, 2010, 31(3): 195-200. doi: 10.1097/MNM.0b013e32833310fa

[9]

Fujiwara H, Maeda Y, Nawa Y, et al. The utility of positron emission tomography/computed tomography in the staging of extranodal natural killer/T-cell lymphoma[J]. Eur J HaematolEur J Haematol, 2011, 87(2): 123-129. doi: 10.1111/j.1600-0609.2011.01645.x

[10]

Khong PL, Pang CBY, Liang R, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies[J]. Ann HematolAnn Hematol, 2008, 87(8): 613-621. doi: 10.1007/s00277-008-0494-8

[11]

岳建兰, 尹亮, 黄世明, 等. 鼻型结外NK/T细胞淋巴瘤的¹⁸F-FDG PET/CT表现及分期[J]. 中国医学影像学杂志, 2017, 25(7): 487-490, 495. doi: 10.3969/j.issn.1005-5185.2017.07.002
Yue JL, Yin L, Huang SM, et al. ¹⁸F-FDG PET/CT manifestation and staging of nasal extranodal NK/T-cell lymphoma[J]. Chin J Med ImagingChin J Med Imaging, 2017, 25(7): 487-490, 495. doi: 10.3969/j.issn.1005-5185.2017.07.002

[12]

Liu C, Zhang Y, Zhang Y, et al. Diagnostic value of ¹⁸F-FDG PET/CT for cutaneous extranodal natural killer/T-cell lymphoma, nasal type[J]. Nucl Med CommunNucl Med Commun, 2016, 37(5): 446-452. doi: 10.1097/MNM.0000000000000463

[13]

杜晓庆, 郁春景, 万卫星. ¹⁸F-FDG PET/CT在结外鼻型自然杀伤/T细胞淋巴瘤中的应用价值[J]. 中华核医学与分子影像杂志, 2016, 36(6): 490-494. doi: 10.3760/cma.j.issn.2095-2848.2016.06.06.003
Du XQ, Yu CJ, Wan WX. Clinical value of ¹⁸F-FDG PET/CT in patients with extranodal nasal type natural killer/T-cell lymphoma[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2016, 36(6): 490-494. doi: 10.3760/cma.j.issn.2095-2848.2016.06.06.003

[14]

展凤麟, 张依凡, 刘昕, 等. ¹⁸F-FDG PET/CT 代谢参数在鼻型结外NK/T淋巴瘤诊断中价值[J]. 医学影像学杂志, 2019, 29(9): 1467-1470.
Zhan FL, Zhang YF, Liu X, et al. The value of ¹⁸F-FDG PET/CT metabolic parameters in the diagnosis of extranodal nasal type NK/T lymphoma[J]. J Med ImagingJ Med Imaging, 2019, 29(9): 1467-1470.

[15]

Zhou ZY, Chen CY, Li X, et al. Evaluation of bone marrow involvement in extranodal NK/T cell lymphoma by FDG-PET/CT[J]. Ann HematolAnn Hematol, 2015, 94(6): 963-967. doi: 10.1007/s00277-014-2289-4

[16]

Koh Y, Lee JM, Woo GU, et al. FDG PET for evaluation of bone marrow status in T-cell lymphoma[J]. Clin Nucl MedClin Nucl Med, 2019, 44(1): 4-10. doi: 10.1097/RLU.0000000000002320

[17]

章莹, 周锦, 王莉, 等. 结外NK/T细胞淋巴瘤治疗前正电子发射计算机断层扫描显像中骨髓¹⁸F-脱氧葡萄糖摄取形态预测预后的价值[J]. 中华肿瘤杂志, 2020, 42(10): 885-890. doi: 10.3760/cma.j.cn112152-20191115-00739
Zhang Y, Zhou J, Wang L, et al. Prognostic value of bone marrow ¹⁸F-FDG uptake pattern of pretreatment PET-CT in extranodal NK/T cell lymphoma[J]. Chin J OncolChin J Oncol, 2020, 42(10): 885-890. doi: 10.3760/cma.j.cn112152-20191115-00739

[18]

Kwong YL. Natural killer-cell malignancies: diagnosis and treatment[J]. LeukemiaLeukemia, 2005, 19(12): 2186-2194. doi: 10.1038/sj.leu.2403955

[19]

Horwitz SM, Ansell SM, Ai WZ, et al. NCCN guidelines insights: T-Cell lymphomas, version 2.2018[J]. J Natl Compr Canc NetwJ Natl Compr Canc Netw, 2018, 16(2): 123-135. doi: 10.6004/jnccn.2018.0007

[20]

Kim SJ, Choi JY, Hyun SH, et al. Risk stratification on the basis of Deauville score on PET-CT and the presence of Epstein-Barr virus DNA after completion of primary treatment for extranodal natural killer/T-cell lymphoma, nasal type: a multicentre, retrospective analysis[J/OL]. Lancet Haematol, 2015, 2(2): e66−e74[2020-12-10]. https://www.sciencedirect.com/science/article/abs/pii/S2352302615000022. DOI: 10.1016/S2352-3026(15)00002-2.

[21]

Huang JJ, Zhu YJ, Xia Y, et al. A novel prognostic model for extranodal natural killer/T-cell lymphoma[J]. Med OncolMed Oncol, 2012, 29(3): 2183-2190. doi: 10.1007/s12032-011-0030-x

[22]

Bai B, Huang HQ, Cai QC, et al. Predictive value of pretreatment positron emission tomography/computed tomography in patients with newly diagnosed extranodal natural killer/T-cell lymphoma[J]. Med OncolMed Oncol, 2013, 30(1): 339-. doi: 10.1007/s12032-012-0339-0

[23]

张亚飞, 王珍, 林丽莉, 等. 治疗前¹⁸F-FDG PET/CT SUV_max对Ⅰ~Ⅱ期鼻型NK/T细胞淋巴瘤的预后判断价值[J]. 中华核医学与分子影像杂志, 2018, 38(9): 602-604. doi: 10.3760/cma.j.issn.2095-2848.2018.09.005
Zhang YF, Wang Z, Lin LL, et al. Prognostic value of pretreatment ¹⁸F-FDG PET/CT SUV_max on stageⅠ-Ⅱ extranodal nasal type natural killer/T-cell lymphoma[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2018, 38(9): 602-604. doi: 10.3760/cma.j.issn.2095-2848.2018.09.005

[24]

Chang Y, Fu XR, Sun ZC, et al. Utility of baseline, interim and end-of-treatment ¹⁸F-FDG PET/CT in extranodal natural killer/T-cell lymphoma patients treated with L-asparaginase/pegaspargase[J/OL]. Sci Rep, 2017, 7(1): 41057[2020-12-10]. https://www.nature.com/articles/srep41057. DOI: 10.1038/srep41057.

[25]

Song MK, Chung JS, Shin HJ, et al. Clinical value of metabolic tumor volume by PET/CT in extranodal natural killer/T cell lymphoma[J]. Leuk ResLeuk Res, 2013, 37(1): 58-63. doi: 10.1016/j.leukres.2012.09.011

[26]

吴丽玲, 梁金花, 王莉, 等. ¹⁸F-脱氧葡萄糖PET-CT代谢参数对晚期结外NK/T细胞淋巴瘤的预后预测价值[J]. 中华肿瘤杂志, 2019, 41(11): 831-836. doi: 10.3760/cma.j.issn.0253-3766.2019.11.006
Wu LL, Liang JH, Wang L, et al. Prognostic value of pretreatment ¹⁸F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma[J]. Chin J OncolChin J Oncol, 2019, 41(11): 831-836. doi: 10.3760/cma.j.issn.0253-3766.2019.11.006

[27]

Pak K, Kim BS, Kim K, et al. Prognostic significance of standardized uptake value on F18-FDG PET/CT in patients with extranodal nasal type NK/T cell lymphoma: a multicenter, retrospective analysis[J]. Am J OtolaryngolAm J Otolaryngol, 2018, 39(1): 1-5. doi: 10.1016/j.amjoto.2017.10.009

[28]

Kim CY, Hong CM, Kim DH, et al. Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on ¹⁸F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2013, 40(9): 1321-1329. doi: 10.1007/s00259-013-2443-6

[29]

莫奕文, 李璐, 李沅桦, 等. PET代谢参数在结外鼻型NK/T细胞淋巴瘤中的预后价值[J]. 肿瘤影像学, 2019, 28(5): 306-314. doi: 10.19732/j.cnki.2096-6210.2019.05.004
Mo YW, Li L, Li YH, et al. Prognostic value of PET metabolic parameters in patients with extranodal NK/T-cell lymphoma, nasal type[J]. OncoradiologyOncoradiology, 2019, 28(5): 306-314. doi: 10.19732/j.cnki.2096-6210.2019.05.004

[30]

Ko KY, Liu CJ, Ko CL, et al. Intratumoral heterogeneity of pretreatment ¹⁸F-FDG PET images predict disease progression in patients with nasal type extranodal natural killer/T-cell lymphoma[J]. Clin Nucl MedClin Nucl Med, 2016, 41(12): 922-926. doi: 10.1097/RLU.0000000000001375

[31]

Jiang C, Zhang X, Jiang M, et al. Assessment of the prognostic capacity of pretreatment, interim, and post-therapy ¹⁸F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type[J]. Ann Nucl MedAnn Nucl Med, 2015, 29(5): 442-451. doi: 10.1007/s12149-015-0964-8

[32]

Jiang C, Liu J, Li L, et al. Predictive approaches for post-therapy PET/CT in patients with extranodal natural killer/T-cell lymphoma: a retrospective study[J]. Nucl Med CommunNucl Med Commun, 2017, 38(11): 937-947. doi: 10.1097/MNM.0000000000000731

[33]

Khong PL, Huang BS, Lee EYP, et al. Midtreatment ¹⁸F-FDG PET/CT scan for early response assessment of SMILE therapy in natural killer/T-cell lymphoma: a prospective study from a single center[J]. J Nucl MedJ Nucl Med, 2014, 55(6): 911-916. doi: 10.2967/jnumed.113.131946

[34]

Minamimoto R, Fayad L, Advani R, et al. Diffuse large B-cell lymphoma: prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for early therapeutic monitoring[J]. RadiologyRadiology, 2016, 280(1): 220-229. doi: 10.1148/radiol.2015150689

[35]

Jauw YWS, Zijlstra JM, de Jong D, et al. Performance of ⁸⁹Zr-labeled-rituximab-PET as an imaging biomarker to assess CD20 targeting: a pilot study in patients with relapsed/refractory diffuse large B Cell lymphoma[J/OL]. PLoS One, 2017, 12(1): e0169828[2020-12-10]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0169828. DOI: 10.1371/journal.pone.0169828.

[36]

Capobianco N, Meignan M, Cottereau AS, et al. Deep-learning ¹⁸F-FDG uptake classification enables total metabolic tumor volume estimation in diffuse large B-cell lymphoma[J]. J Nucl MedJ Nucl Med, 2021, 62(1): 30-36. doi: 10.2967/jnumed.120.242412